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a,b TunisiaAims: Cystatin C is an endogenous marker of renal function. It is a well established better marker of glomerular
filtration rate than serum creatinine. There is also evidence that cystatin C is associated with atherosclerotic disease.
The present prospective study evaluated the prognostic value of cystatin C after myocardial infarction in patients
without chronic kidney disease.
Methods and results: A total of 127 patients who underwent coronary angiography after an acute coronary syn-
drome (ACS) were included. Cystatin C was associated with the severity of coronary artery disease (CAD). Cystatin
C levels were significantly higher in patients with 3-vessels disease and severe CAD according to GENSINI score
(p = 0.01 and p < 0.001 respectively). Among the patients admitted for ST elevation myocardial infarction, Cystatin
C concentration was correlated with the initial TIMI flow in the culprit artery (p < 0.001). Mean duration of the
follow-up period was 10.76 þ 2.1 months. High Cystatin C concentrations were associated to the occurrence of unfa-
vourable outcomes and cardiovascular mortality during follow-up (1.19 þ 0.4 vs. 1.01 þ 0.35 mg/L, p = 0.01 and
1.21 þ 0.36 vs. 0.96 þ 0.27 mg/L, p = 0.03). Among different laboratory parameters, cystatin C was the best marker to
predict the occurrence of major adverse cardiovascular events during the follow-up (Area under the receiveroperat-
ing characteristic curve = 0.743).
Conclusion: High cystatin C levels are associated with the severity of coronary artery disease in patients present-
ing an acute coronary syndrome and a normal renal function. Cystatin C is also associated to unfavourable cardio-
vascular outcomes during follow-up and appears as a strong predictor for risk of cardiovascular events and death.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
CKD Chronic kidney disease
HD hemodialysis
LVFS left ventricular fractional shortening
TDI Tissue Doppler imaging
BSA Body surface area
BNP brain natriuretic peptide
BP blood pressure
TTE transthoracic echocardiography
LA left atrial
IVST interventricularseptal thickness
LVPWT left ventricular posterior wall thickness
LVEDd left ventricular end-diastolic dimension
LVESd left ventricular end-systolic dimension
LVMi left ventricular mass index
2D-LVEDVi two-dimensional left ventricular end diastolic
volume index
2D-LVESVi two-dimensional left ventricular end systolic
volume index
LVFS left ventricular fractional shortening
LVEFs left ventricular ejection fraction calculated by
biplane Simpson method
3D-LVEDVi three-dimensional left ventricular end dias-
tolic volume index
3D-LVESVi three-dimensional left ventricular end systolic
volume index
3D-LAEDVi three-dimensional left atrial end diastolic
volume index
3D-LAESVi three-dimensional left atrial end systolic
volume index
3D-LVEF three-dimensional left ventricular ejection
fraction
3D-LAEF three-dimensional left atrial ejection fraction
GLS two-dimensional global longitudinal strain
GRS two-dimensional global regional strain
GCS two-dimensional global circumferential strain
LAS left atrial strain
RVS right ventricular strain
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CYSTATIN C: A PROGNOSTIC MARKERIntroduction
The risk stratification of patients with coronaryartery disease (CAD), especially death and
acute heart failure, has been the subject of
research in recent years [1–3]. Renal impairment
is frequent in patients with cardiovascular disease
and increases morbidity and mortality. The search
for new biomarkers with better and accurate pro-
files has been very intense. Cystatin C (Cys C) is a
novel marker for renal dysfunction and is better
than serum creatinine, especially for mild renal
impairment [4–6]. Cys C is a cysteine protease
inhibitor produced in all nucleated cells at a con-
stant rate and is freely filtrated by the glomeruli
to be reabsorbed and degraded in the proximal
tubules. Cys C is not affected by sex, age, and
muscle mass. Recently, a close relationship has
been established between Cys C and various sub-
sets of atherosclerotic disease including CAD,
stable CAD, as well as acute coronary syndromes
(ACS). Therefore, Cys C might be a useful biomar-
ker for prognostic stratification in patients with
ACS [7–9].
The aim of the present study was to evaluate
whether the concentration of Cys C could predict
the severity of CAD after myocardial infarction in
patients with normal or mildly impaired renal
function estimated from the concentration of
serum creatinine, and to determine the prognostic
value of Cys C in predicting cardiovascular death
during follow up.3D-GLS three-dimensional global longitudinal strainMethods
Our study was prospective observational
including Tunisian patients admitted to the
department of cardiology of Hédi Chaker Hospital
with the diagnosis of myocardial infarction who
underwent urgent coronary angiography from
May 2012 to December 2012. All patients have
the following criteria: (1) chest pain at rest within
the past 24 hours; (2) ST-segment elevation; (3)
new presumed left bundle brunch block; or (4)
ST segment or T wave abnormalities with tro-
ponin Ic rise. All patients were admitted in the
hospital within the past 24 hours. Patients were
divided into two groups: Group 1 was defined by
patients admitted with non-ST segment elevation
myocardial infarction (NSTEMI) with troponin Ic
rise and Group 2 included patients with ST-
segment elevation myocardial infarction (STEMI).
We excluded patients with chronic renal failure
and those who had an estimated glomerular filtra-tion rate (eGFR) <60 mL/min, calculated using the
Modification of Diet in Renal Disease equation
based on the level of serum creatinine from this
study. Patients with significant valvular or struc-
tural heart disease were excluded. All the study
participants provided their consent before enter-
ing the study. Patients with hypertension were
defined by a blood pressure P140/90 mmHg or
having history of antihypertensive drug use. Dia-
betes mellitus was defined as fasting glucose level
>1.26 g/L (7 mmol/L) or having history of hypo-
glycemic drug or insulin use. Dyslipidemia was
defined as a low density lipoprotein-cholesterol
level >1.4 g/L (3.6 mmol/L) or if patients were tak-
ing a hypolipidemic drug. Smokers were defined
as patients actively inhaling tobacco smoke. The
hemodynamic status was evaluated at admission,
including blood pressure measurement and the
KILLIP class. For patients admitted with NSTEMI,
Table 1. Baseline characteristics of the study population (127 patients).
Variables All patients (n = 127) Group 1: NSTEMI (n = 43) Group 2: STEMI (n = 84) p
Quantitative variables Mean (SD)
Age (y) 58 (11.65) 56.17 (13.6) 59.2 (10.5) NS
Sex (M:F) 105:22 35:8 70:14 NS
BMI (kg/m2) 29.56 (7.8) 28.41 (9.6) 30.18 (5.7) NS
GRACE risk score 123.12 (24.5) 120.35 (17.5) 143.42 (19.6) 0.02
eGFR (MDRD) (mL/min) 98.8 (30.9) 105.2 (25.8) 89.6 (23.7) 0.03
Scr (lmol/L) 92.9 (30.6) 86.4 (24.6) 98.5 (28.5) 0.03
Cystatin C (mg/L) 1.04 (0.36) 0.99 (0.28) 1.13 (0.25) 0.03
BNP (pg/mL) 275.2 (367.9) 212.7(258.1) 376.4(381.2) 0.02
LVEF (%) 51.36 (10.8) 54.5 (8.9) 48.12 (9.6) 0.04
Qualitative variables N (%)
HT 52 (40.9) 17 (39.5) 35 (41.6) NS
DM 58 (45.6) 19 (44.1) 39 (46.4) NS
DL 33 (26) 10 (23.2) 23 (27.3) NS
Smokers 81 (63.8) 27 (62.7) 54 (64.2) NS
CF 11 (8.7) 3 (6.9) 8 (9.5) 0.04
BMI = body mass index; BNP = brain natriuretic peptide; CF = family history of premature ischemic heart disease; DL = dyslipidaemia; DM = diabetes
mellitus; eGFR (MDRD) = estimated glomerular filtration rate by Modification of Diet in Renal Disease formula; HT = hypertension; LVEF = left
ventricular ejection fraction; NS = not significant; NSTEMI = non ST-elevation myocardial infarction; Scr = serum creatinine; SD = standard deviation;
STEMI = ST elevation ejection infarction.
Table 2. Angiographic characteristics of the study population.
Characteristic Patients [n (%)]
Vessels with significant lesions
1 vessel 46 (36.2%)
2 vessels 45 (35.4%)
3 vessels 36 (28.3%)
Left main disease 14 (11%)
CAD severity score
Mild CAD (GENSINI score 1–20) 55 (43.3%)
Severe CAD (GENSINI score >20) 72 (56.7%)
Infarct-related vessel (STEMI)
LAD 45 (53.5%)
CX 26 (31%)
RC 13 (15.5%)
CAD = coronary artery disease; CX = circumflex artery; LAD = left
anterior descending artery; RC = right coronary artery; STEMI = ST-
elevation myocardial infarction.
FU
LL LEN
G
TH
 A
RTIC
LE
Table 3. Cystatin C levels and severity of coronary artery
disease in the study population (127 patients).
Cystatin C
(mg/L)a
p
Vessels with significant lesions
1-VD 0.93 (0.24) 0.01
2-VD 1.04 (0.34)
3-VD 1.17 (0.47)
CAD severity score
Mild CAD (GENSINI score 1–20) 0.87 (0.19) <0.001
Severe CAD (GENSINI score >20) 1.12 (0.24)
CAD = coronary artery disease; VD = vessel disease.
a All values are expressed as mean (standard deviation).
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chemical tests were collected at admission before
coronary angiography. The serum concentration
of Cys C was determined with a turbidimetric
immunoassay (COBAS INTEGRA Cystatin C 400
Roche). Serum creatinine was determined using
the Jaffe reaction. GFR was calculated using the
Modification of Diet in Renal Disease study
equation (mL/min): 186.3  (serum crea-
tinine/88.4)1.154  (age)0.203  (0.742 if female).
An echocardiographic study was performed
before discharge and during the follow-up. Left
ventricular ejection fraction (LVEF) was calculated
using the Simpson biplane method. Left ventricu-
lar systolic dysfunction was defined as an LVEF
<50%. Coronary angiography was performed inall patients through radial or femoral access. The
results of the coronary angiography were evalu-
ated by at least three operators. Significant angio-
graphic stenosis was defined as >50% in any of the
major epicardial coronary arteries. Left anterior
descending artery, left circumflex, and right coro-
nary artery were examined to determine the num-
ber of stenotic arteries as 0–3-vessel disease. The
involvement of the left main artery was evaluated
as a 2-vessel disease. The severity of CAD was
scored according to the number of stenotic arter-
ies and the GENSINI score. The two CAD groups
were determined according the GENSINI score,
mild CAD (score 0–20), and severe CAD (score
>20). All patients were followed-up during
12 months. The follow-up was assessed by phone
or clinical review. The circumstances of death
were determined by interviews with relatives or
hospital records. During follow up, the major
Table 4. Cystatin C levels and severity of coronary artery
disease in patients with NSTEMI (Group 1 = 43 patients).
Cystatin C
(mg/L)a
p
Vessels with significant lesions
1-VD 0.96 (0.24) 0.003
2-VD 1.08 (0.49)
3-VD 1.34 (0.60)
CAD severity score
Mild CAD (GENSINI score 1–20) 0.84 (0.21) 0.001
Severe CAD (GENSINI score >20) 1.10 (0.11)
CAD = coronary artery disease; VD = vessel disease.
a All values are expressed as mean (standard deviation).
Table 5. Cystatin C levels and severity of coronary artery
disease in patients with STEMI (Group 2 = 84 patients).
Cystatin C
(mg/L)a
p
Vessels with significant lesions
1-VD 0.82 (0.16) 0.018
2-VD 0.93 (0.30)
3-VD 1.11 (0.55)
CAD severity score
Mild CAD (GENSINI score 1–20) 0.89 (0.15) <0.001
Severe CAD (GENSINI score >20) 1.18 (0.12)
Initial TIMI flow
TIMI 0 1.52 (0.21) <0.001
TIMI 1 1.26 (0.24)
TIMI 2 0.99 (0.26)
TIMI 3 0.90 (0.27)
CAD = coronary artery disease; TIMI flow = Thrombolysis In Myocar-
dial Infarction flow; VD = vessel disease.
a All values are expressed as mean (standard deviation).
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CYSTATIN C: A PROGNOSTIC MARKERadverse cardiovascular events (MACE) were
recorded. The MACE included cardiovascular
death, reinfarction, ACS, or acute heart failure
requiring rehospitalization.Statistical analysis
Statistical analysis was performed using PSS
version 18.0 (Chicago, IL, USA). Laboratory
parameters were presented as the mean (standardTable 6. Major adverse cardiac events in the study population.
MACE All patients
n = 127
Death 6 (4.7%)
Myocardial reinfarction 6 (4.7%)
NSTEMI 13 (10.3%)
Heart failure 7 (5.5%)
MACE = major adverse cardiovascular events; NS = not significant; NSTEMIdeviation). Correlations between continuous vari-
ables were assessed using Pearson’s or Spear-
man’s correlation analysis. The Student t test
was used to compare means between groups,
and the Chi-square test was used to compare pro-
portion between groups. Analysis of variance was
used for multigroup comparison. A receiver-
operating characteristic curve analysis was used
to identify the optimal cut-off points of Cys C for
predicting CAD. A value of p < 0.05 was consid-
ered as statistically significant. Survival analysis
included Kaplan-Meier representations for the
time to event data.Results
A total of 127 patients were admitted in our car-
diology department with the diagnosis of ACS.
The demographic and clinical features for the
study population are summarized in Table 1.
On admission, 105 patients (82.6%) were hemo-
dynamically stable with no signs of heart failure
(KILLIP class I). The angiographic characteristics
of the study population are listed in Table 2.
Among the 127 patients, 94 underwent successful
percutaneous coronary intervention (final Throm-
bolysis in Myocardial Infarction flow III) and three
had no reflow. A total of 11 patients underwent
coronary artery bypass surgery and 19 had medi-
cal treatment only.
Among the 43 patients admitted with NSTEMI,
Cys C levels were significantly higher in patients
with ST-segment depression (1.47 ± 0.35 and
1.08 ± 0.23 respectively, p = 0.01) and in patients
presenting a left bundle brunch block (1.64 ± 0.38
and 1.10 ± 0.19 respectively, p = 0.006). Cystatin C
concentration was also higher in patients with ele-
vated GRACE risk score >140 (1.37 ± 0.21 and
1.01 ± 0.24 respectively, p = 0.04).
Cys C levels were significantly higher in
patients with 3-vessels disease and severe CAD
according to GENSINI score compared with the
other groups (Tables 3–5). Among the patients
admitted for STEMI, Cys C concentration was cor-
related with the initial Thrombolysis in Myocar-
dial Infarction flow in the culprit arteryGroup 1
n = 43
Group 2
n = 84
p
1 (2.3%) 5 (9.2%) 0.01
2 (4.6%) 4 (4.7%) NS
8 (18.6%) 5 (5.9%) 0.02
3 (6.9%) 4 (4.7%) NS
= nonST-elevation myocardial infarction.
Table 7. Association between laboratory parameters and major
adverse cardiac events during follow-up.
Variable MACEa p
Yes No
Cystatin C (mg/L) 1.19 (0.4) 1.01 (0.35) 0.01
Creatinine (lmol/L) 101.26 (32.5) 90.31 (29.7) 0.08
Urea (mmol/L) 7.34 (2.74) 6.6 (2.57) 0.16
Uric acid (lmol/L) 371.50 (115.9) 322.10 (108.4) 0.03
BNP (pg/mL) 315.80 (224.5) 232.46 (210.0) 0.05
BNP = brain natriuretic peptide; MACE: =major adverse cardiovascular
events.
a All values are expressed as mean (standard deviation).
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in patients having no-reflow after percutaneousFigure 1. Receiver-operating characteristic curves analyses for cystatin
occurrence of major adverse cardiovascular events during the follow-up p
Table 8. Comparison of clinical and laboratory characteristics acco
study population.
Variables Favourable out
Mean blood pressure (mmHg) 103 (19)
Cystatin C (mg/L) 0.96 (0.27)
Creatinine (lmol/L) 91.65 (29.8)
Urea (mmol/L) 6.67 (2.58)
Uric Acid (lmol/L) 360.45 (113.6)
BNP (pg/mL) 247.05 (325.7)
Ejection fraction (%) 54 (17)
BNP = brain natriuretic peptide; NS = not significant.
a All values are expressed as mean (standard deviation).coronary intervention but without significant dif-
ference (1.19 ± 0.16 and 1.12 ± 0.15, respectively).
During hospitalization, the maximum of KILLIP
class reached was II in 11 patients (8.6%), III in
three patients (2.3%), and 23 patients (18.1%) pre-
sented hemodynamic deterioration. These
patients had greater Cys C concentration
(0.96 ± 0.24 vs. 0.78 ± 0.19, p < 0.001). Furthermore,
Cys C levels were higher in patients presenting
global systolic left ejection fraction impairment
(1.04 ± 0.2 vs. 1.02 ± 0.4, p = 0.3).
Long-term follow-up data were available for all
patients. The follow-up period was
10.76 ± 2.1 months. During this period, 32 patients
(25.2%) presented at least one MACE and sixC, creatinine, uric acid, and brain natriuretic peptide in predicting
eriod in the study population. BNP = brain natriuretic peptide.
rding to occurrence of death during the follow-up period in the
comea Deatha p
107 (21) NS
1.21 (0.36) 0.03
117.09 (37.2) 0.04
8.69 (2.33) NS
381.21 (108.7) NS
536.97 (605.7) 0.04
39 (12) 0.03
Figure 2. Occurrence of death during the follow-up period according to cystatin C, evaluated with Kaplan-Meier survival curve.
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CYSTATIN C: A PROGNOSTIC MARKERpatients (4.7%) died. The group of patients with
STEMI had a poor prognosis and presented more
myocardial reinfarction and heart failure during
the follow-up than the patients who presented
with NSTEMI (Table 6).
Cys C and uric acid were associated with the
occurrence of unfavorable outcomes during
follow-up (Table 7). The accuracy of these param-
eters in predicting MACE, evaluated using the
area under the receiver-operating characteristic
curve, was moderate. Among these parameters,
Cys C was the best marker to predict occurrence
of MACE during the follow-up (Fig. 1). For a cut-
off value of 0.97 mg/L, Cys C had a sensitivity of
84% and a specificity of 66% for prediction MACE.
The patients who died had greater Cys C, crea-
tinine, and brain natriuretic peptide levels and
lower LVEF (Table 8). The risk of cardiovascular
death was multiplied by 4.8 for patients with ele-
vated Cys C levels >1.2 mg/L (p = 0.01). The cumu-
lative survival of patients with high Cys C
concentration was significantly lower during the
follow-up (Fig. 2). Furthermore, combined GRACE
score and Cys C levels showed that the risk of car-
diovascular death in patients with NSTEMI and
GRACE score >140 was 2.5 times higher if Cys C
concentration was >1.2 mg/L (p = 0.02).Discussion
It is well known that chronic kidney dysfunction
in patients with CAD is common and increases
morbidity and mortality. Heart and kidney func-
tions are strongly associated and it is known that
the dysfunction of one of these organs necessarily
damages the other [10,11]. Thus, even mild renal
impairment is associated with high cardiovascular
risk. Cys C, a cysteine protease inhibitor, is a novel
marker for renal function. It has been shown that
Cys C is more sensitive and specific for GFR esti-
mation than creatinine. In fact, Cys C is less influ-
enced by sex, age, and muscle mass and is a better
marker for detection of mild renal impairment
[12].
Cys C is produced by all nucleated cells. Ische-
mia and hypoxia increases Cys C production by
the cardiomyocytes. By its cysteine protease activ-
ity, Cys C regulates the inflammatory response,
the phagocytic activity, and participates in the bal-
ance of production and degradation of extracellu-
lar matrix [13]. Therefore, this marker could be
associated with the development and progression
of atheroma plaque [14,15] and it might be a good
prognostic biomarker in patients with myocardial
infarction.
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with normal GFR (eGFR >60 mL/min) who under-
went coronary angiography, we demonstrated
that higher Cys C levels were correlated to the
severity of CAD attested by the number of stenotic
arteries and GENSINI score. This was consistent
with the findings of previous study. In fact, some
studies have shown that Cys C is closely related
to CAD, both in stable CAD as well as in patients
presenting ACS (STEMI and NSTEMI). Koenig
et al. [7], Wang et al. [16], and Koc et al. [17] have
previously demonstrated that higher Cys C levels
were associated with CAD and that among differ-
ent renal parameters; Cys C was the best predictor
of coronary angiographic severity. However, in
another study, Niccoli et al. [18] had found that
Cys C was proportional to the number of stenotic
arteries but did not predict lesion complexity or
CAD severity in patients admitted for ACS.
Furthermore, the results of our study showed
the prognostic value of Cys C. Higher concentra-
tions of Cys C were associated with worse clinical
outcomes and cardiovascular death during the
follow-up period. Among other renal parameters,
Cys C was the best predictor of death and MACE.
The risk of death was 4.8 times greater for patients
with Cys C levels >1.2 mg/L. Therefore, the prog-
nostic value of this biomarker had been investi-
gated in several studies. Indeed, previous studies
demonstrated that Cys C was associated to greater
cardiovascular risk and mortality. Silva et al. [19]
suggested that patients admitted for STEMI and
who presented elevated Cys C levels (P0.84 mg/
L) on admission, had greater risk of progression
to cardiogenic shock or death during hospitaliza-
tion. In this same study, only Cys C levels
P0.84 mg/L and impaired LVEF <40% were pre-
dictors of the risk of death during the follow-up.
Ichimoto et al. [20], in a population of 71 patients
with STEMI, had also suggested the prognostic
value of Cys C, high concentrations of this marker
were associated with greater frequency of rehos-
pitalization and acute heart failure episodes. Asso-
ciation of Cys C with greater mortality rate during
follow-up was also observed in other studies in
patients admitted with NSTEMI [21,22]. A recent
study [23] on 660 patients with diabetes and ACS
suggested that Cys C was the best renal marker
for predicting death at long-term. A Cys C value
of 1.6 mg/L predicted mortality during follow-up
with sensitivity around 72% and specificity of
71%. Manzaro et al. [24] had demonstrated that
GRACE score combined to Cys C levels improved
risk stratification in NSTEMI (hazard ratio 2.25;
confidence interval 95%; 1.61–3.15; p < 0.001).Conclusion
Cys C is a novel sensitive marker of mild renal
impairment (not detected by creatinine). Its role
in the development of atherosclerosis and CAD
may be due to its cysteine protease activity, mod-
ulating the vascular inflammatory response. The
results of our study suggest that high Cys C levels
indicate the severity of CAD in patients with ACS
and normal renal function. Cys C is also a strong
predictor for risk of cardiovascular events and
death. Therefore, it can be a good prognostic mar-
ker for risk stratification after ACS.
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